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Abstract
Background: Vitamin B12 deficiency is a common disorder. In circulation, vitamin B12 is bound to transcobalamin
(holotranscobalamin), which is considered the active form of cobalamin. The objective of this study was to evaluate the
analytical performance of the Roche Elecsys Active B12 immunoassay.
Methods: Limit of quantification and linearity were assessed according to CLSI EP17-A2 and EP-6A guidelines. Precision
and bias of Roche Active B12 test against Architect ci8200 (Abbott) were performed according to CLSI EP-5 A3 guideline
at three European laboratories. Precision requirements were set at <4% for within-run precision and <15% for inter-
mediate precision. Requirements for method comparison were set at a slope of 1.00 20%. In addition, 95% reference
interval was conducted in European adults according to CLSI-EP28 guideline.
Results: The assay was shown to be linear and precise and met the requirements. Lot-to-lot variation and lab-to-lab
variation both were 4%. Method comparison with Abbott Architect showed a significant bias of 9 pmol/L, which
increases to up to 23 pmol/L around the current medical decision point. The 95% reference interval of the Roche Elecsys
Active B12 test was determined at 37–188 pmol/L.
Conclusion: Although Roche Elecsys Active B12 immunoassay met the requirements, this test has a positive bias of
9 pmol/L, which led to an increase in lower limit of reference interval compared with Abbott test. This test first needs to
be clinically validated before it can be applied as a first-line screening test in the diagnosis of vitamin B12 deficiency.
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Introduction
Vitamin B12 deficiency is common and occurs particu-
larly among the elderly. The diagnosis of vitamin B12
deficiency is hampered by the availability of good bio-
markers. Clinical vitamin B12 deficiency with classical
haematological and neurological symptoms also
known as pernicious anaemia is relatively uncommon
and is estimated to affect 2–3% of individuals of
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65 years and older.1–3 More often, subclinical vitamin
B12 deficiency occurs which, depending on the chosen
cut-off value of vitamin B12, ranges from 3% to 26% in
the general population.4
Vitamin B12 is mainly derived from animal sources,
and after ingestion, it is bound to haptocorrin in the
stomach. In the duodenum, vitamin B12 is released
from haptocorrin and binds to intrinsic factor after
which it is taken up in the enterocytes of the distal
ileum. In circulation, about 20% of vitamin B12 is
bound to transcobalamin (holotranscobalamin,
holoTC), which is the active form of vitamin B12 avail-
able to cells, while the remaining 80% is bound to
haptocorrin.
The diagnosis of vitamin B12 deficiency is hampered
by the availability of biomarkers with good diagnostic
performance. Most frequently, total vitamin B12 is
measured in serum or plasma as first-line test to esti-
mate an individual’s vitamin B12 status. Several years
ago, the active B12 assay became available, which
enabled the measurement of holoTC on the Abbott
routine platform. As this holoTC assay is not ham-
pered by fluctuations in haptocorrin, it was expected
to result in better diagnostic performance. Several stud-
ies have assessed the diagnostic performance of holoTC
(or active B12) and have shown a marginally better per-
formance of the active B12 test compared with total
vitamin B12.
5–7 In addition, homocysteine and methyl-
malonic acid (MMA) are frequently used as functional
markers of vitamin B12.
3,8,9 Most laboratories use total
vitamin B12 or active B12 as first-line test, which is
followed by MMA or homocysteine as second-line
test9. The medical decision point is based at either an
active B12 <20 pmol/L or in case active B12 is between
20 and 35 pmol/L by a follow-up test like MMA or
homocysteine. For the diagnosis of vitamin B12 defi-
ciency, it is of utmost importance to have access to
biomarkers for vitamin B12 deficiency such as total
vitamin B12 and active B12. At this moment, active
B12 is available at Abbott Architect and was recently
introduced by Siemens ADVIA centaur and Roche
Diagnostics, which facilitates the availability of active
B12 in clinical chemistry laboratories.
In this study, we performed a multicentre analytical
evaluation of the Roche ElecsysVR Active B12 immunoas-
say and assessed linearity, precision and bias by method
comparison between cobas e 411 (Roche Diagnostics)
and Architect ci8200 (Abbott) and determined the
95% reference interval in European individuals.
Material and methods
This study was executed between October 2016 and
May 2017. Analytical performance of the Active B12
assay was evaluated on a cobas e 411 analyzer
(Roche Diagnostics GmbH, Penzberg, Germany).
Precision and method comparison were evaluated in
three laboratories; Labor Limbach in Heidelberg,
Germany, Erasmus MC, Rotterdam, The Netherlands
and Synlab, Munich, Germany. Precision was evaluat-
ed in all three laboratories, and method comparison
was evaluated in two laboratories that used WHO
03/178 standardized Abbott reagents, i.e. Heidelberg
and Rotterdam.
Analytical performance
Analytical performance of the Roche Active B12
immunoassay was assessed at cobas e 411 using
reagent lot 245198 99 (Roche Diagnostics GmbH,
Penzberg, Germany).
Limit of Blanc, limit of detection, limit of quantitation. Limit
of Blanc (LoB) and limit of detection (LoD) were deter-
mined by measuring 10 times an analyte-free sample in
six runs. LoB and LoD were calculated according to
CLSI EP17-A2. Limit of quantitation (LoQ) was cal-
culated according to CLSI EP17-A2; eight samples
with low concentrations (between 3.2 and 8.7 pmol/L,
respectively) were measured in five-fold on five days,
and the coefficient of variation (CV%) was calculated
per sample. LoQ is defined at the lowest concentration
at which CV <10%.
Linearity. Linearity of the Active B12 assay was assessed
by diluting three high analyte serum samples with dil-
uent. Fifteen concentrations from above the upper limit
throughout the measuring range and below the lower
end of the specified measuring range were prepared
(measuring range; between 3 and 150 pmol/L). The
dilutions were measured in three-fold within a single
run using one lot. Evaluation was performed according
to CLSI EP6A guideline using a validated software tool
provided by Roche Diagnostics Penzberg Biometry
department. All the measured data of each dilution
series were analysed in a respective regression analysis.
Data were analysed using linear, quadratic and cubic
order least square regression analysis according to
CLSI guidelines. Specifications were predefined at
0.8 pmol/L at a concentration below 8 pmol/L and
<10% for concentrations between 8 and 150 pmol/L.
Interference. Interference of the Active B12 assay for bil-
irubin, haemoglobin, intralipids and biotin was
assessed by diluting a sample without interfering sub-
stance with a sample with interfering substance. For
bilirubin interference, this was assessed at three concen-
trations 32.9, 74.2 and 145 pmol/L of active B12 using a
serum sample with 66mg/dL (1129 lmol/L) bilirubin.
Haemoglobin interference was assessed at 29.7, 71.5
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and 137 pmol/L of active B12 using a serum sample
with 1000mg/dL (0.621 mmol/L) haemoglobin.
Intralipid interference was assessed at 27.3, 65.6 and
125 pmol/L using a serum sample with 2000mg/dL
intralipids. Biotin interference was assessed at 34.1,
70.4 and 120 pmol/L active B12 using a serum sample
with 100 ng/mL biotin. Recovery was calculated, and
for analyte concentrations of 3–8 pmol/L, the maxi-
mum allowed deviation was specified at 0.8 pmol/L;
for concentrations between >8–100 pmol/L, the devia-
tion was set at 10%, and for concentrations
>100 pmol/L, the deviation is set at 15%.
Sample stability. Sample stability at –20C was deter-
mined by calculating the recovery of four human serum
samples with different active B12 concentrations (i.e.
13, 44, 76 and 141 pmol/L) in triplicate for six
months at –20 5C). Specification for recovery was
set at 10% for analyte concentrations >8 pmol/L.
Multicentre validation
Precision. Precision of the ElecsysVR Active B12 immuno-
assay was assessed at each laboratory on a cobas e 411
analyzer (Roche Diagnostics GmbH, Penzberg,
Germany) by measuring the same set of samples; two
levels of controls (PreciControl Active B12, provided by
Roche Diagnostics GmbH, Penzberg, Germany) and
five concentrations of pooled human serum samples
(provided by Roche Diagnostics GmbH, Penzberg,
Germany) with two reagent lots and one Calset cali-
brator set consisting of two levels of calibrators at the
cobas e 411 analyzers according to CLSI-EP5 A3 pro-
tocol. At each laboratory, five replicates of each sample
(PreciControl and human serum pools) were measured
for five days in one run per day for each reagent lot
(1980 Lot and 1990 lot, provided by Roche Diagnostics
GmbH, Penzberg, Germany). All samples used for pre-
cision were shipped on dry ice and were stored at –20C
before testing. Intermediate precision of Abbott
Architect Active B12 was reported <6% (Abbott
Architect Active-B12, package insert October 2015).
Within-precision and intermediate precision were calcu-
lated for each laboratory using Excel (version 2.30). Lot-
to-lot variation was calculated by calculating the mean
of each lot per laboratory after which the mean, stan-
dard deviation and coefficient of variation of the two
lots were calculated. Lab-to-lab variation was calculated
by calculating individual means of a single lot (1980) for
each laboratory after which the mean, standard devia-
tion and coefficient of variation were calculated.
Bias. At each laboratory, a minimal amount of 120
anonymized left-over human serum patient samples,
in which active B12 was routinely measured by the
Architect Active B12 assay (Abbott, Architect,
Chicago, USA), were collected and stored at –20C
until measurement. Samples were collected at each lab-
oratory according to predefined percentages covering
the measuring range: 10% <25 pmol/L; 30% with
active B12 between 25 and 50 pmol/L; 20% with
active B12 between 50 and 100 pmol/L and 10% of
active B12 >100 pmol/L. One reagents lot of Roche
Elecsys immunoassay (MP lot, Roche Diagnostics,
standardized against WHO 03/178), one level of
Roche CalSet Active B12 calibrators consisting of two
levels of calibrators and two levels of Roche
PreciControls were used for method comparison).
Two lots of Abbott active B12 reagents (both traceable
against the WHO 03/178 [lot 10556UP00] [Erasmus
MC] and lot 10557UP00 [Heidelberg]), four levels of
controls (two commercial controls and two in-house
serum pools) and two calibrator sets consisting each
of six levels of calibrators were used in this study.
Samples were thawed at room temperature and were
homogenized gently by inverting the tubes and were
centrifuged at 4000 g for approximately 4 min. The
supernatant then was transferred into a new qualified
tube immediately and was used for testing. Each
sample was measured at the same day on both cobas
e 411 as Architect ci8200 analyzer at 1 run per day
and 1 days. Weighted Deming regression was applied
by method comparison function in Analyse-it for Excel
(version 2.30). Bland-Altman bias plots were obtained
by Analyse-it for Excel plotting the absolute difference
between cobas e 411 (Roche Diagnostics) and Architect
ci8200 (Architect) in pmol/L against mean active B12
concentrations in pmol/L. Normality of residuals was
assessed by visual inspection of the histogram.
Reference interval
Serum samples were collected from apparently healthy
adults at one site operated by the German Blood
Transfusion Service in Bavaria, Germany. Two hun-
dred and fifty-two samples with approximately 50%–
50% male–female distribution and with age from 20 to
79 had been selected. Homocysteine concentrations
were determined in all samples using cobas
Homocysteine assay (Roche Diagnostics). Only sam-
ples with homocysteine concentration <15 lmol/L
were selected for Active B12 measurements. In total,
214 of 252 samples qualified, and these were random-
ized and sent to all three laboratories. Two reagent lots
have been used, with MP Lot at Erasmus MC and
Heidelberg and PoQ Lot at Munich. For all samples
with measurement results above measuring range, a 1:2
dilution was made and the samples were measured
again. As only 1:2 dilution is allowed by the package
insert, all samples that are still above measuring limit of
Heil et al. 3
150 pmol/L after 1:2 dilution are considered
‘>300 pmol/L’ in the analysis. In total, one sample
had an active B12 concentration >300 pmol/L. 95%
reference ranges were calculated using non-parametric
methods in accordance with CLSI EP28-A3.a
Results
Analytical performance
In this experiment, the LoB was calculated to be
0.66 pmol/L and LoD was 0.78 pmol/L. The LoQ of
this experiment demonstrated a CV of 2.9% at the
lowest tested active B12 concentration of 3.2 pmol/L.
From these results, the lower limits of measurements
for the Elecsys Active B12 assay were decided to be set
at: LoB¼ 2.0pmol/L, LoD¼ 3.0 pmol/L and LoQ¼
5.0pmol/L. Samples were shown to be linear between
3.0 and 150pmol/L active B12 with an absolute devia-
tion of 0.8pmol/L in the lower range (3–8pmol/L) and
a relative deviation of 10% in the range between 8 and
150pmol/L. Interference for bilirubin was not detected
up to a concentration of 66mg/dL (1129lmol/L). For
haemoglobin, intralipids and biotin interference could
not be detected up to concentrations of 1000mg/dL
(0.621 mmol/L) haemoglobin, 2000mg/dL intralipids
and 40 ng/mL biotin (164 nmol/L). Samples were
stable at –20C for six months.
Precision
Two data points from the human serum pool (HSP05
were excluded from the analysis (Munich site, HSP05, 1
from MP Lot and 1 from PoQ lot), as they were above
the measuring range. All other data points were used
for precision analysis. Within-run precision of Roche
ElecsysVR Active B12 immunoassay was <4% at each
centre, and intermediate precision was <6% at each
centre (Table 1). Lot-to-lot variation was <4% and
lab-to-lab variation was <3.1%.
Bias
One hundred and forty-seven samples were used for
method comparison at the Heidelberg site and 142 dif-
ferent samples were measured at the Erasmus MC site.
Method comparison of cobas e 411 compared with
Architect ci8200 resulted at the Heidelberg site in a
constant bias of 11 pmol/L and a proportional bias of
10% (0.90 [95%CI 0.83–0.98] xþ 11.28 [95%CI 8.28–
14.27], R¼ 0.94, P< 0.0001, n¼ 147). At the Erasmus
MC site, this resulted in a significant constant bias of
8 pmol/L and no significant proportional bias (0.99
[95%CI 0.88–1.09] xþ 7.52 [95% [95% CI 3.20–
11.84], R¼ 0.93, P<0.0001, n¼ 142). Combined results
from Heidelberg and Rotterdam resulted in a small T
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significant constant bias of 9 pmol/L and no significant
proportional bias compared with Abbott Architect
(y¼ 0.96 [95%CI 0.88–1.02]xþ 8.6 [95% CI 5.8–11.4],
R¼ 0.94, P< 0.001, n¼ 289, Figure 1(a)). The differ-
ence plot of combined results of Rotterdam and
Heidelberg shows a significant constant bias of
6.6 pmol/L (95% CI 5.7 pmol/L till 7.5 pmol/L) com-
pared with Abbott Architect (Figure 1(b)) with an
agreement range of –8.9–22.2 pmol/L. This bias
shows a negative trend proportional to the magnitude
of measurement showing a higher bias when the active
B12 concentration becomes lower.
Reference interval of active B12
Median active B12 concentration in serum of 214 sam-
ples was 77 pmol/L. The 95% reference interval
of Roche Active B12 assay was calculated at
37–188 pmol/L.
Discussion
Active B12 is commonly used as biomarker in the diag-
nosis of vitamin B12 deficiency. In this study, we eval-
uated the new RocheVR Elecsys Active B12 assay at the
cobas e 411 instrument at three European sites and
showed that the assay is linear and precise but shows
a bias around the current medical decision range
(20–35 pmol/L) based on Abbott Architect.
The RocheVR Elecsys Active B12 assay was shown to
be precise with an intermediate precision lower than
6%, which is comparable to Abbott Architect interme-
diate precision of <6% (Abbott Architect Active-B12,
package insert October 2015). Lab-to-lab variation and
lot-to-lot variation both were small, enabling harmoni-
zation of test results and facilitating the use of general
cut-off values in clinical algorithms. Method compari-
son showed a small constant bias of 9 pmol/L. Visual
inspection of the bias plot shows that the observed bias
is not constant over the measuring range. Roche Active
B12 results within the lower range have a larger bias,
which is expected to result in a higher active B12 test
result (up to 22 pmol/L) around the current clinical
decision point of 20–35 pmol/L.
Current diagnosis of vitamin B12 using active B12
is in most laboratories a two-step process, in which
active B12 is applied as first-line test. If active B12 is
<21 pmol/L, then the diagnosis of vitamin B12 deficien-
cy is confirmed if clinical signs are present. However, if
the test result is between 21 and 35 pmol/L, a follow-up
test is performed by measuring MMA to confirm diag-
nosis because specificity of the active B12 test is too low
within this range. Patients with active B12> 35 pmol/L
are unlikely to be diagnosed with vitamin B12 deficien-
cy. However, these cut-off values are mostly based on
the Abbott Active B12 test. In this study, however, we
have shown that the reference interval of Roche Active
B12 is considerably higher (37–188 pmol/L) making the
current cut-off values not suitable. Novel cut-off values
of Roche Active B12 should be established by calculat-
ing sensitivity and specificity of active B12 concentra-
tions against MMA concentrations before this test can
be applied as first-line screening test in the diagnosis of
vitamin B12 deficiency.
In future, clinical algorithms would benefit from
standardization against an active B12 reference
method using commutable standards in the assay.
Figure 1. Bias plot of active B12 assay at Roche cobas e 411 compared with Abbott Architect. (a) Weighted Deming regression of
active B12 at Roche cobas e 411 plotted against Abott Architect ci8200. (b) Bland-Altman bias plot showing the absolute difference
between cobas e 411 and Architect ci8200 plotted against mean of active B12 in pmol/L.
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This multicentre evaluation of the Roche Elecsys
Active B12 assay demonstrates excellent precision. A
bias compared with Abbott Architect Active B12
assay was observed, which needs to be accounted by
establishment of laboratory-specific reference intervals.
Before this assay can be implemented on Roche routine
platforms, a clinical validation of the Roche active B12
test is needed to establish reliable cut-off values to
define clinical- and subclinical vitamin B12 deficiency.
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